Glutarate Compounds for Ischemia-Reperfusion Tissue Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ischemia-reperfusion injuries, such as those occurring during heart attacks or strokes, do not effectively address the debilitating tissue damage caused by ischemia and reperfusion, leading to high morbidity and mortality.
Innovation Solution
Administration of glutarate compounds, specifically α-ketoglutarate (α-KG), 2-hydroxyglutaric acid, or (S)-2-hydroxyglutaric acid, in therapeutically effective amounts before, during, or after the ischemic event to prevent, inhibit, or treat ischemia-reperfusion injuries.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard declotting and antiplatelet treatments are administered during reperfusion, then patient survival is improved, but tissue/organ damage from ischemia and reperfusion is not addressed
Solution Approach 1:
The patent administers glutarate compounds (α-KG, 2-HG, or S-2HG) before the ischemic event or at the onset of reperfusion to pre-condition tissues and mitigate damage before it occurs. This preliminary intervention protects mitochondrial function and reduces infarct size, addressing tissue damage that standard treatments fail to prevent.
2Use of energy by moving object
If reperfusion is performed to save patient life, then oxygen supply is restored, but ischemia-reperfusion injury is caused to tissues
Solution Approach 1:
The patent converts the harmful reperfusion process into a beneficial intervention by administering glutarate compounds during reperfusion. These compounds modulate mitochondrial permeability transition pore opening and reduce oxidative stress, transforming the previously harmful reperfusion event into a protective therapeutic window that limits tissue damage while maintaining oxygen supply.
3Reliability
If glutarate compounds are administered in high doses, then therapeutic effect is enhanced, but potential toxicity increases
Solution Approach 1:
The patent optimizes the dosage parameters of glutarate compounds to achieve therapeutic effects while minimizing toxicity. Clinical trials administered α-KG at doses of 5-20 mg/kg (typically 10-15 mg/kg) as single bolus injections, achieving significant reduction in infarct size and improvement in cardiac function without observed adverse effects. This parameter optimization balances efficacy and safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The glutarate compounds significantly reduce tissue damage by improving heart functional recovery and reducing infarct size, restoring heart function, and inhibiting ATP synthase, thereby providing rapid protection against ischemia-reperfusion injuries.
Implementation Method 1
inhibiting ATP synthase, thereby providing rapid protection against ischemia-reperfusion injuries
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Disclosed herein are methods of preventing, inhibiting, reducing, or treating ischemia and reperfusion injury to tissues with glutarate compounds such as alpha-ketoglutarate.